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Novavax Inc. and Generex Biotechnology Corp. led gains by biopharmaceutical 
companies after the World Health Organization said seven Indonesians may 
have contracted avian influenza from other humans. Bloomberg.com May 24
th 
2006. 
 
Remington Arms Company: Stocks in this firearms manufacturer fell sharply after 
it was discovered that the company’s previously announced ‘cure’ for the Avian 
Flu was nothing more than the model 1100 Classic Trap Shotgun.  The 
Onion.com July 18
th 2006.  
 
 
The future of biotechnology is an increasingly emotive subject.  It is also of growing interest to 
geographers.  From speculation about the risks to global biosecurity, the promise of safety 
through biometric surveillance, the hope of new pharmaceuticals, the opportunities for 
expanding agricultural production, or disgust at new forms of biological manipulation, 
biotechnology is proceeding through a series of affective appeals to our deep-seated hopes 
and fears.  Such speculations also make claims about the kinds of spatialities we inhabit, 
stressing the importance of borders, boundaries, enclosures and surveillance.  If the recent 
claims for future applications of the life sciences are amassed, we find our selves and our 
bodies located at the centre of a global triage system, subject to a fantastical array of 
technological devices, drug regimes, medical and agricultural products, which promise to treat 
the ailments that define us, curing individual disease, protecting state security, or feeding the 
world.  Such biotechnological imaginaries define our pathologies, yet at the same time they 
offer us hopes of salvation, or at least corporeal alleviation.  The speculative business of 
biotechnology is increasingly to ignite both our fears and our hopes at the same time. 
 
Yet for all these heady emotions, I want to suggest that biotechnology is a funny business as 
well.  This too is a speculative claim, but it is an argument I want to try and make by drawing 
on a different emotional repertoire: that of humour, irony and ambiguity.  You’ll have to bear 
with me, there isn’t a punchline.  I’m also hesitant in my delivery.  To point out the potential 
comedy that comes with the conjoined narratives of danger and hope in biotechnological 
discourses feels like tempting fate.  I’ll be holding my breath until this comes to print and 
maybe ruing it shortly after.  The problem is that the avian flu virus will mutate, someone will 
try and use some form of biological agent in a terrorist attack, there will be further unfortunate deaths for those left in the wake of the pursuit of better medical treatment for the fortunate.  
These things have happened before, and they will happen again.  So where is the humour 
here?  Perhaps this is my point.  The increasingly shrill speculations around the future of 
biology have left little space for us to reflect outside of their anxious embrace, to question the 
trajectory of particular pathogens through society, to chart alternative connections between 
biology and the politics of health and security, to think differently about strategies for 
cultivating the well-being of all kinds of organisms.  We both fear and desire change, and the 
promissory futures of biotechnology draw affectively on these fears and fetishes.  A little 
humour might enable us the space to think differently.   
 
So why is this a pertinent issue now?  There are a few developments in the life sciences that 
mean the material effect of these speculative discourses is increasing.  The impact that 
expectations have in directing the development of any particular technology are now well 
documented in what science and technology studies call the sociology of expectations (Brown 
and Michael 2003).  Such reviews show us what is at stake in defining a technology as 
something new, or alternatively locating it within established trajectories (Jasanoff 2005).  It 
also shows us how expectations in biotechnology have changed over time. That is, the way 
the future was once represented is different to the way it has been represented more recently 
(Brown and Michael 2003).  This is in large part due to the growth of scientists as 
entrepreneurs as well as researchers.  In standing to benefit from a short term rise in stock 
value, there are now more incentives to make strong claims about the future, notwithstanding 
the uncertainties evident in current research activity or the indeterminacies of long term 
performance.  This then links to a further form of analysis, about the particular salience of 
speculative capital at this historical moment (Cooper 2006a, Sunder Rajan, forthcoming).  
Speculation is not new to capitalism.  What is crucial to the analysis here is that speculation 
appears to be both more intense and at the same time less coupled to a material basis in 
profit than at any other time in the history of capitalism.  As Kaushik Sunder Rajan puts it, ‘it is 
not that abstraction replaces materialism, but rather that the abstractions that represent value 
are more and more distantly coupled (ontologically and temporally) from their materialist 
bases’ (forthcoming).   
 
It is also possible to suggest there are changes in the tropes through which biotechnological 
speculation is operating.  Going back to Mulkay’s classic analysis of the rhetorics of hope and 
fear in analysis of debates over embryo research, there are hopes expressed around these 
new technologies, and so too there are fears (Mulkay, 1993).  These dualities still exist.  But 
what seems of increasing salience is appeal to a more brutal form of biopolitical rhetoric that 
links discourses of bodily security explicitly to biotechnological futures.  There is perhaps a 
new rationality of life being forged in the response of biotechnology companies to what 
Melinda Cooper has termed the ‘biological turn in the war on terror’ (Cooper, 2006b).  
Security is increasingly defined in human and biological terms, and so biotechnological hopes and fears are defined in concert, capitalizing on the opportunity to offer individuals and 
governments protection in ways that militarize the politics of biotechnology, through new 
drugs and new biosecurity regimes that seek to insulate human and animal populations from 
exterior risks (see for example Braun, 2006).  In the same way that Mulkay suggests the UK 
parliamentary debates about embryology demonstrated the apparent unassailability of 
representations that evoked ‘hope’ (Mulkay, 1993), so too these dual representations of hope 
and fear can appear equally irrefutable, leaving little space for alternative voices. 
 
Finally then, there is frustration that there is no obvious place to occupy which is outside of 
these material and discursive circuits.  Whilst it might be possible to explore the material 
bases of such speculations, to seek to denaturalise these projects, their discourses cannot be 
so easily discounted, for the reality of them operates precisely in the realm of potential, that is 
the potential to materialise new markets (Sunder Rajan, forthcoming).  It is not possible to 
avoid the affective economies of hope and fear through which such promissory futures are 
constructed.  Speculation is a central performative repertoire in these contemporary bio-
economies and cannot be side-stepped by cynicism about the basis for making such claims; 
rather a different form of engagement with the discourses, materiality, performativity and 
accountability of speculation itself is required.   
 
So what strategies are there to engage differently with these politics of biotechnological 
speculation?  It is perhaps too easy to be pulled into tracing the construction of these darkly 
emergent worlds, following the science as it moves towards a teleological future and thus to 
tell stories that accentuate their discursive force.  I would tentatively suggest there are other 
productive modes of engagement, which might both challenge and expand the scope of 
biotechnological speculation, through seeking to capture our imaginations in different ways.  If 
engaging with affective economies of hope and fear, affect becomes a political strategy.  And 
in puncturing the apparently seamless construction of networks of biotechnological risk and 
innovation, irony and humour are potentially transformative tools.  As Donna Haraway puts it, 
‘irony is about contradictions that do not resolve into larger wholes, even dialectically, about 
the tension of holding incompatible things together because both or all are necessary and true. 
Irony is about humour and serious play. It is also a rhetorical strategy and a political method.’ 
(Haraway, 1991, p.149).  Recourse to a critical attitude and an absurdist humour might just be 
a productive way to begin to open up spaces to see the politics of biology differently. 
 
What I am not suggesting, however, is a distancing form of irony.  Indeed, I want to suggest 
we could usefully look first to the humour inherent within biology itself.  Originally writing at the 
end of the US involvement within Vietnam, and recently cited within Richard Mabey’s book of 
reflections on nature and emotion (Mabey, 2006), the biologist Joseph Meeker suggests that 
there is comedy within biological processes themselves.  Evolution, he argues,  
 ‘proceeds as an unscrupulous, opportunistic comedy, the object of which 
appears to be the proliferation of as many life forms as possible.  Successful 
participants in it are those who live and reproduce even when times are 
dangerous, not those who are best able to destroy enemies or competitors. Its 
ground rules for participants, including people, are those that also govern literary 
comedy; organisms must adapt themselves to their circumstances in every 
possible way, must studiously avoid all or nothing choices, must seek 
alternatives to death, must accept and revel in maximum diversity, must 
accommodate themselves to the accidental limitations of birth and environment, 
and must prefer cooperation to competition, yet compete successfully when 
necessary […] Comedy is a strategy for living that contains ecological wisdom, 
and it may be one of our best guides (Meeker, 1974, cited in Mabey, 2006, 
p.200).  
 
Comedy as a strategy for living eschews the essentialism and anthropocentrism that feature 
in these linear narratives of biological risk, and challenges the emphasis on destruction in the 
pursuit of purity that emerges frequently in biosecurity strategies.  A few examples 
demonstrate the diversity of paths that biological agents can take as they are woven into the 
fabric of society and nature relations.  Take for example the incongruous history of the 
Botulinum Toxin, a neurotoxic protein produced by the bacteria Clostridium botulinum.  It first 
emerged of interest to science as a cause of food poisoning, was later considered as an 
agent in chemical warfare or biological terrorism, and subsequently as a medical treatment for 
involuntary muscle spasm.  It is now routinely and voluntarily injected into consumer 
foreheads during lunch breaks to temporarily keep the signs of ageing at bay, leaving it not at 
all clear which populations now need to be protected against Botox®.  Ironies are also evident 
over an evolutionary time scale.  Biologists are only now recognising the function of the viral 
remnants within our DNA and the productive role played by viruses in ‘species development, 
in the creation of new genes, and even in the evolution itself’ (MacPhail, 2004, p. 325), just at 
the point when the value of biosecurity regimes for humans and for animals appear to be 
premised on the impossible promise of developing disease-free populations.   
 
Defining the materiality of what is a biological agent itself becomes a matter of some dark 
humour for authorities seeking to govern biotechnological risks.  As Brian Balmer asks in a 
forthcoming paper, ‘which is more dangerous: the four page patent specification for VX nerve 
gas or Nesquik milkshake powder?’ (Balmer, 2006, p. 691).  The trajectories traced in the 
paper suggest a more complicated answer than might first appear.  Whilst Terry Olsen was 
quickly arrested by the FBI and imprisoned for sending himself a mixture of sugar and 
chocolate Nesquik he claimed was anthrax in the wake of the World Trace Centre attacks in 
2001, the security implications of publishing the patent on the chemical warfare agent, VX, in 
1975, is conversely treated with relative nonchalance by British Ministers.  As I have written about elsewhere, humour also features centrally in public debates about the claims made for 
the future of biotechnology, in this case in speculations around the potential options for organ 
transplantation (Davies, 2006).  Here, humour is a device that challenges the universalising 
claims made in the life sciences, relocating these through the contingencies and comedies of 
inhabiting a singular and often unpredictable body.  Again, these are not trivial exchanges, but 
serve to de-reify expectations by drawing attention to the gaps that open up between personal 
embodied experiences and entrepreneurial claims, as people reflect on what it might mean to 
materially inhabit the new bodies that are proposed.   
 
So, in tracing the speculative trajectories of the life sciences, I would argue there is an 
opportunity for using humour and irony to think about the metaphors of life we evoke, the 
kinds of subjectivities we engage, the performativity of the narratives we write, and the ways 
in which we might stage more creative debates about the future of biotechnology.  Recent 
work by urban geographers on different strategies for engaging with the city demonstrates 
just how imaginative some of these forms of research and writing can be in opening up ideas 
about how to live cities differently (see for example Pinder, 2005).  As the life sciences 
increasingly shape the contours of our bodies, the boundaries of the states and the forms of 
sociality we are likely to inhabit, we too need experimentation that opens up attention to the 
inevitable subversions and inherent openness of the relations between biology, space and 
society.  Laughter might just turn out to be a good medicine, even if we don't have or want the 
closure that a punchline would supply. 
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